Q-omics provides the consensus-scored CPT1C profile across patient tissues and cancer cell-line models. CPT1C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CPT1C is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, CPT1C RNA expression shows 16,780 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, LIHC, and PCPG as cancer lineages where CPT1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPT1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPT1C survival associations across molecular data types. CPT1C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPT1C RNA expression–survival associations across cancer types. High CPT1C expression shows unfavorable associations in KIRP, BLCA, UVM, STAD, ACC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CPT1C RNA expression.
This table summarizes CPT1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CPT1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPT1C shows lower tumor expression in KICH and higher tumor expression in LIHC, KIRC, LUAD, CHOL and LUSC. The LIHC box plot shows higher CPT1C RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with CPT1C in patient tissues and cancer cell lines. In patient samples, CPT1C shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, CPT1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
